Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion

Karim H. Saba, Louise Cornmark, Marianne Rissler, Thoas Fioretos, Kristina Åström, Felix Haglund, Andrew E. Rosenberg, Otte Brosjö, Karolin H. Nord

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Conventional osteosarcoma is the most common primary malignancy of bone. This group of neoplasms is subclassified according to specific histological features, but hitherto there has been no correlation between subtype, treatment, and prognosis. By in-depth genetic analyses of a chondroblastoma-like osteosarcoma, we detect a genetic profile that is distinct from those previously reported in benign and malignant bone tumors. The overall genomic copy number profile was less complex than that typically associated with conventional osteosarcoma, and there was no activating point mutation in any of H3F3A, H3F3B, IDH1, IDH2, BRAF, or GNAS. Instead, we found a homozygous CDKN2A deletion, a DMD microdeletion and an FN1-FGFR1 gene fusion. The latter alteration has been described in phosphaturic mesenchymal tumor. This tumor type shares some morphological features with chondroblastoma-like osteosarcoma and we cannot rule out that the present case actually represents an FN1-FGFR1 positive malignant phosphaturic mesenchymal tumor of bone without osteomalacia.

Original languageEnglish (US)
JournalGenes Chromosomes and Cancer
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Chondroblastoma
Gene Fusion
Osteosarcoma
Bone and Bones
Neoplasms
Osteomalacia
Point Mutation
Malignant mesenchymal tumor

Keywords

  • bone tumor
  • chondroblastoma
  • DNA mate-pair sequencing
  • fusion gene
  • next generation sequencing
  • RNA sequencing
  • sarcoma
  • SNP array

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion. / Saba, Karim H.; Cornmark, Louise; Rissler, Marianne; Fioretos, Thoas; Åström, Kristina; Haglund, Felix; Rosenberg, Andrew E.; Brosjö, Otte; Nord, Karolin H.

In: Genes Chromosomes and Cancer, 01.01.2019.

Research output: Contribution to journalArticle

@article{3f84471e31154067a1d027d5d449a995,
title = "Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion",
abstract = "Conventional osteosarcoma is the most common primary malignancy of bone. This group of neoplasms is subclassified according to specific histological features, but hitherto there has been no correlation between subtype, treatment, and prognosis. By in-depth genetic analyses of a chondroblastoma-like osteosarcoma, we detect a genetic profile that is distinct from those previously reported in benign and malignant bone tumors. The overall genomic copy number profile was less complex than that typically associated with conventional osteosarcoma, and there was no activating point mutation in any of H3F3A, H3F3B, IDH1, IDH2, BRAF, or GNAS. Instead, we found a homozygous CDKN2A deletion, a DMD microdeletion and an FN1-FGFR1 gene fusion. The latter alteration has been described in phosphaturic mesenchymal tumor. This tumor type shares some morphological features with chondroblastoma-like osteosarcoma and we cannot rule out that the present case actually represents an FN1-FGFR1 positive malignant phosphaturic mesenchymal tumor of bone without osteomalacia.",
keywords = "bone tumor, chondroblastoma, DNA mate-pair sequencing, fusion gene, next generation sequencing, RNA sequencing, sarcoma, SNP array",
author = "Saba, {Karim H.} and Louise Cornmark and Marianne Rissler and Thoas Fioretos and Kristina {\AA}str{\"o}m and Felix Haglund and Rosenberg, {Andrew E.} and Otte Brosj{\"o} and Nord, {Karolin H.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/gcc.22764",
language = "English (US)",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion

AU - Saba, Karim H.

AU - Cornmark, Louise

AU - Rissler, Marianne

AU - Fioretos, Thoas

AU - Åström, Kristina

AU - Haglund, Felix

AU - Rosenberg, Andrew E.

AU - Brosjö, Otte

AU - Nord, Karolin H.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Conventional osteosarcoma is the most common primary malignancy of bone. This group of neoplasms is subclassified according to specific histological features, but hitherto there has been no correlation between subtype, treatment, and prognosis. By in-depth genetic analyses of a chondroblastoma-like osteosarcoma, we detect a genetic profile that is distinct from those previously reported in benign and malignant bone tumors. The overall genomic copy number profile was less complex than that typically associated with conventional osteosarcoma, and there was no activating point mutation in any of H3F3A, H3F3B, IDH1, IDH2, BRAF, or GNAS. Instead, we found a homozygous CDKN2A deletion, a DMD microdeletion and an FN1-FGFR1 gene fusion. The latter alteration has been described in phosphaturic mesenchymal tumor. This tumor type shares some morphological features with chondroblastoma-like osteosarcoma and we cannot rule out that the present case actually represents an FN1-FGFR1 positive malignant phosphaturic mesenchymal tumor of bone without osteomalacia.

AB - Conventional osteosarcoma is the most common primary malignancy of bone. This group of neoplasms is subclassified according to specific histological features, but hitherto there has been no correlation between subtype, treatment, and prognosis. By in-depth genetic analyses of a chondroblastoma-like osteosarcoma, we detect a genetic profile that is distinct from those previously reported in benign and malignant bone tumors. The overall genomic copy number profile was less complex than that typically associated with conventional osteosarcoma, and there was no activating point mutation in any of H3F3A, H3F3B, IDH1, IDH2, BRAF, or GNAS. Instead, we found a homozygous CDKN2A deletion, a DMD microdeletion and an FN1-FGFR1 gene fusion. The latter alteration has been described in phosphaturic mesenchymal tumor. This tumor type shares some morphological features with chondroblastoma-like osteosarcoma and we cannot rule out that the present case actually represents an FN1-FGFR1 positive malignant phosphaturic mesenchymal tumor of bone without osteomalacia.

KW - bone tumor

KW - chondroblastoma

KW - DNA mate-pair sequencing

KW - fusion gene

KW - next generation sequencing

KW - RNA sequencing

KW - sarcoma

KW - SNP array

UR - http://www.scopus.com/inward/record.url?scp=85065969084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065969084&partnerID=8YFLogxK

U2 - 10.1002/gcc.22764

DO - 10.1002/gcc.22764

M3 - Article

C2 - 31066955

AN - SCOPUS:85065969084

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

ER -